byl 719

Alpelisib (BYL-719) is a PI3Kα inhibitor (IC50=5 nM) with selective, potent, and oral activity, inhibiting PI3Kβ γ δ with low activity (IC50=250 290 1200 nM). Alpelisib demonstrates antitumor activity and specifically targets PIK3CA mutant tumors.

Alpelisib hydrochloride (BYL-719 hydrochloride) exhibits anticancer properties[1][2]. As a potent and selective PI3Kα inhibitor with high oral bioavailability, it has IC50 values of 5 nM for p110α, 250 nM for p110γ, 290 nM for p110δ, and 1200 nM for p110β, indicating its efficacy in targeting enzymes involved in cancer cell proliferation.